Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

68.37 +1.35 (+2.01%)
Streaming Delayed Price Updated: 1:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
42 43 Next >
Thailand-Developed System Can Draw Out More COVID-19 Vaccine Doses: All You Need To Know
Researchers in Thailand have developed a machine to draw out COVID-19 vaccine doses more efficiently and optimize lower-than-expected supplies. According to researchers at... 
Via Benzinga
Exposures COVID-19
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Exposures COVID-19 Interest Rates Product Safety
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
Global Stocks & Commodities Update
A quick look at oil, cobalt, and some of the stocks in my portfolio. 
Via Talk Markets
Unusual Options Activity Insight: AstraZeneca
On Thursday, shares of AstraZeneca (NASDAQ:AZN) saw unusua... 
Via Benzinga
3 Top COVID Vaccine Stocks That Wall Street Is Bullish About
Hint: Pfizer, BioNTech, and Moderna didn't make the list. 
Via The Motley Fool
Exposures COVID-19
Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial?
AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to... 
Via Benzinga
AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%
A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo.... 
Via Benzinga
Exposures COVID-19
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... 
Via Benzinga
Exposures Product Safety
Here's What Recent News From the FDA Means for AstraZeneca
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost. 
Via The Motley Fool
Exposures Product Safety
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
From AstraZeneca
Via Business Wire
Are COVID-19 Vaccines Effective Against Delta Variant? Probably Not So Much
COVID-19 vaccines from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Oxford–AstraZeneca Plc (NASDAQ: AZN) have shown effectiveness... 
Via Benzinga
Exposures COVID-19
Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial
AstraZeneca Plc's (NASDAQ: AZN) bispecific antibody derived from Compugen Ltd's (NASDAQ: CGEN) COM902 will advance into clinical development. ... 
Via Benzinga
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
Cannabis Movers & Shakers: Jay-Z-Backed The Parent Co. Appoints First Black CEO In Major Public Cannabis Company, CannaSafe, HEXO And Delta 9 Each Announce New Appointments
CannaSafe's CEO Departure, New Management Team Appointed Amid Reorganization Cannabis testing laboratory CannaSafe... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Here's What This Label Expansion Means for AstraZeneca Investors
The recent decision by the EMA to approve Forxiga for the treatment of chronic kidney disease is a huge boost for the pharmaceutical company. 
Via The Motley Fool
3 Top Biotech Stocks to Buy in August
Each of these companies makes for a great vehicle to play an aging demographic. 
Via The Motley Fool
Sunday Update - UK Disarray, Brazilian Kisses
News from the UK, China and Brazil, with the latest from Cosan. 
Via Talk Markets
Is AstraZeneca a Bargain Buy?
Even if you aren't crazy about the company's COVID-19 vaccine, this is still a growth investment worth considering for your portfolio. 
Via The Motley Fool
Exposures COVID-19
Moderna's Shot Seems To Have A Better Shot Against Delta Than Pfizer's
Besides proudly stating that its Covid-19 shot produced a "robust" antibody response against the highly contagious delta variant last Thursday, Moderna (NASDAQ: MRNA)... 
Via Benzinga
Exposures COVID-19
Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders? EMA Investigates Possible Links
The European Medicines Agency is investing a possible link between mRNA vaccines and erythema multiforme or two kidney disorders by a few recipients of the shots.... 
Via Benzinga
Exposures COVID-19
Facebook Blocks Russia Based Ad Agency Behind COVID-19 Vaccine Smear Campaign
Facebook Inc (NASDAQ: FB) removed multiple accounts linked to a mysterious advertising agency operating out of Russia that sought to pay social media influencers to deride... 
Via Benzinga
Exposures COVID-19
Britain Study Shows Restricted Use Of AstraZeneca COVID-19 Shot Associated With No Clot Cases: Reuters
Following a decision to restrict the use of University of Oxford / AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in those under the age of 40 years, no new cases... 
Via Benzinga
Exposures COVID-19
The Real World
The rise of the delta has caused markets to drop back after the rises earlier although inflation still remains within a point or two of forecasts at 5.3-5.4% annualized. 
Via Talk Markets
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease... 
Via Benzinga
Exposures Product Safety
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3... 
Via Benzinga
AstraZeneca's Forxiga Wins European Approval For Chronic Kidney Disease
The European Union has approved AstraZeneca plc’s (NASDAQ: AZN) Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2... 
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2
From AstraZeneca
Via Business Wire
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis
Sierra Oncology Inc (NASDAQ: SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN) for AZD5153, a potent, and selective BRD4... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.